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The possibility of promising molecules receiving Breakthrough Therapy Designation (BTD) early in their clinical 
lifecycle encourages accelerated development strategies to decrease approval timelines. The speed that these 
projects move through the pipeline has required Genentech’s manufacturing organization to push the limits of 
their manufacturing flexibility in order to support a streamlined approach to scale-up.  
 
Recent accelerated development product manufacturing presented several new operational, logistical and 
technical challenges which required creative solutions to overcome, in order to achieve tight in-process control 
while maintaining agility. This poster will discuss the lessons learned by the manufacturing site while executing 
that Cell Culture manufacturing campaign, including 
 
The benefits and challenges associated with: 
 Process qualification with limited small scale data  
 Operating within a narrow design space 
 Leveraging a clinical facility for process qualification activities 
 Supporting new strategies in an existing facility 
 
 
 
